PCV3: THE COST-EFFECTIVENESS OF TREATING CHLAMYDIA PNEUMONIAE INFECTION FOR THE PREVENTION OF CORONARY HEART DISEASE  by Sanderson, C & Kubin, M
310 Abstracts
research planning exercise. METHODS: The Atrial Fi-
brillation Antithrombosis Model (AFAM) provides esti-
mates of health and cost outcomes for up to four compet-
ing, user-defined antithrombosis (AT) strategies that may
be used for individuals with atrial fibrillation (AF). These
include conventional anticoagulation (AC) or enhanced
AT such as improved management of a conventional cou-
marin anticoagulant (e.g., warfarin provided through AC
services) or a new agent with some clinical advantage.
Each strategy is characterized by: (1) patient eligibility
pattern, (2) efficacy, (3) impact on quality of life; (4) dis-
continuation rate; and (5) initial and recurrent cost.
AFAM is based on the Duke Stroke Policy Model (SPM),
a validated natural history simulation that projects the
health and cost outcomes of individuals at risk for stroke
and those who have experienced stroke. As a demonstra-
tion, we applied the model to a research planning exer-
cise. Using AFAM we calculated the threshold efficacy
that would lead to an EAT that is cost-effective (i.e., in-
cremental CE ratio of $50,000.) RESULTS: Assuming
an EAT costs 50% greater than AC, and the relative risk
of stroke for AC is 0.6, then EAT would be cost-effective
if the relative risk for stroke is no less than 0.95. In absolute
terms, a cost-effective EAT would need to reduce annual
stroke risk from 3% down to 2.85%. CONCLUSIONS:
The AFAM takes advantage of a previously developed,
validated natural history simulation model. With relative
ease this can be used to facilitate research planning, trial
analysis and education. Its present application serves to
demonstrate that treatments that are only modestly superior
to existing therapies for stroke prevention can be cost-
effective.
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While cyclöoxygenase-2 inhibitors appear to be safe, hy-
pertensive persons who use rofecoxib may experience in-
creases in systolic blood pressure (SBP). In a randomized
clinical trial involving hypertensive osteoarthritic sub-
jects, use of rofecoxib 25 mg was associated with a 3 mm Hg
increase in systolic blood pressure versus celecoxib 200 mg.
Increased SBP among users of rofecoxib may be associ-
ated with increased risk of cardiovascular disease. OB-
JECTIVE: To estimate excess coronary heart disease
(CHD) and stroke morbidity and mortality associated
with a 3 mm Hg increase in SBP among U.S. adults with
hypertension and osteoarthritis. METHODS: We used
cardiovascular risk prediction models from the Framing-
ham Heart Study and risk factor data from the Third Na-
tional Health and Nutrition Examination Survey to esti-
mate occurrences of CHD and stroke over four years
among osteoarthritic persons with hypertension. We then
estimated the effect of a 3 mm Hg increase in SBP on
event occurrence and costs of cardiovascular disease treat-
ment. RESULTS: An estimated 10.2 million U.S. osteoar-
thritics aged 35 years are hypertensive. Among such
persons, a 3 mm Hg increase in SBP may be associated
with 20,800 additional CHD events (22% fatal) and
21,600 additional stroke events (26% fatal) over four
years. The total cost of treating these events over four
years is estimated to exceed US$650 million in year 2000
constant dollars. CONCLUSION: Increases in SBP asso-
ciated with use of rofecoxib versus celecoxib may trans-
late into significant cardiovascular morbidity and mortal-
ity and impose a sizable economic burden.
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OBJECTIVES: Clinical and epidemiological evidence has
been accumulating for a link between Chlamydia pneu-
moniae and coronary heart disease, but as yet causality is
unproven. The aim of this study was to explore the po-
tential impact and cost-effectiveness of a program of
screening and treatment for C. pneumoniae, assuming a
causal relationship, with a view to informing investment
in definitive trials. METHOD: A spreadsheet model was
used to estimate the impact of different strategies for
screening and treating C. pneumoniae on the incidence of
myocardial infarction and cardiac mortality over a 1-year
post-intervention period, under a range of assumptions.
RESULTS: Screening would potentially be most cost-effec-
tive in patients aged 35 or more with a history of myo-
cardial infarction (central estimate around £3000 per life-
year saved.). Cost-effectiveness will be similar in those
aged 75–84 with established heart disease but no history
of MI, but inferior for younger patients of this kind, and
poorer for people at elevated CHD risk. Sensitivity analy-
sis confirmed that the factors that affect the additional
cost of treatment of survivors of CHD (e.g. length of sur-
vival after prevented death, annual treatment cost for
people with CHD) were all important. The factors that
determine the cost of the screening program (e.g. dura-
tion and daily cost of antibiotic treatment) were also im-
portant, but less so. The results were less sensitive to the
positive predictive value of screening and compliance
with treatment, but these are variables for which wide
ranges of values are plausible. CONCLUSIONS: If cau-
sality of the association between C. pneumoniae and
heart disease were proven, this speculative model sug-
gests that the likely range of costs per life-year saved of a
program of identification and treatment of C. pneumo-
niae targeted at post-MI patients aged 35 or more would
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be comparable with published costings for the use of st-
atins to treat hypercholestolemia.
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OBJECTIVE: It is hypothesized that doxazosin’s positive
impact on lipid metabolism, in addition to its antihyper-
tensive effect, will result in a reduced risk of macrovascular
complications in type 2 diabetics, and an improved cost-
effectiveness profile from the NHS perspective when in-
cluded as a part of a combination drug therapy. METH-
ODS: A Markov model was constructed to simulate the
outcomes of patients on drug combinations over the
course of 10 years. Combination therapies examined in
this analysis were: (1) captopril, frusemide, nifedipine;
(2) atenolol, frusemide, nifedipine; and (3) minimal drug
therapy. The effect of substituting doxazosin in place of
any of these drugs was analyzed. Clinical outcomes con-
sidered included stroke, MI, heart failure, angina, PVD,
and death. Transitional probabilities were based on risk
rates presented in UKPDS 38. Risk rates were adjusted
for age and lipid lowering properties of doxazosin using
Framingham risk equations. The Treatment of Mild Hy-
pertension Study was used to quantify the effect of dox-
azosin on lipid levels. Costs of outcomes were calculated
using a Delphi panel to quantify resource consumption
and economic publications to estimate resource values
from the perspective of the NHS. RESULTS: Patients
who incorporated doxazosin into their combination ther-
apy saved 0.36 additional life-years compared to patients
on other combination regimens. This was achieved at in-
cremental costs ranging from £796–£1,741, which re-
sulted in incremental cost-effectiveness ratios of £2,224–
£4,867. When compared to patients on minimal drug
therapy, patients treated with doxazosin saved 0.71 addi-
tional life-years. This was achieved at incremental costs
ranging from £1,124–£2,089, which led to incremental
cost-effectiveness ratios of £1,574–£2,925. CONCLU-
SIONS: In the UK, the inclusion of doxazosin into an an-
tihypertensive combination drug therapy is predicted to
reduce morbidity and mortality due to diabetic mac-
rovascular complications through a marginal investment
in cost.
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Recently, the Heart Outcomes Prevention Evaluation
(HOPE) trial, a randomized double-blind placebo con-
trolled trial in patients at high risk for cardiovascular
events but who did not have left ventricular dysfunction
or heart failure, demonstrated significant survival and
morbidity benefits associated with ramipril use in the
treatment of these patients. OBJECTIVE: To perform an
economic evaluation of ramipril in the treatment of pa-
tients at high risk of cardiovascular events. METHODS:
A decision analytic model was developed based on the re-
sults reported from the HOPE trial. Data from the trial
were combined with NHS cost data to produce estimates
of the potential incremental cost per life-year saved (IC-
PLYS). Both costs and benefits were discounted at 6%
and both discounted and undiscounted results are pre-
sented. Sensitivity analyses were performed to assess the
robustness of the results to key parameter values. RE-
SULTS: Based on a life—expectancy of 5.89 years esti-
mated for those surviving the trial at 5 years, our base
case estimate of cost-effectiveness is £4,406 per life-year
saved (undiscounted) and £5,544 per life-year saved (dis-
counted). The results were most sensitive to assumptions
around life expectancy of those patients who avoided
death through taking ramipril, and insensitive to the up-
per and lower bounds of costs and clinical events.
CONCLUSIONS: The economic analysis reported here
used clinical outcomes from an RCT together with eco-
nomic data from secondary sources in order to compare
the potential costs and effectiveness of using ramipril or
conventional treatment to treat CVD in high-risk pa-
tients. Based on our base case estimate of £6,327 per life-
year saved (discounted), the findings suggest that treating
patients at high risk of CVD events with ramipril is likely
to be a good investment of NHS resources.
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OBJECTIVES: To evaluate the gender-based differences
in the quality of life (QL) and compliance (C) with rou-
tine ambulatory management of essential hypertensives
(EH) living in Belarus, a European country with unique
combination of the important rise in cardiovascular mor-
bidity and mortality, highly restricted financing the state
health care system, and the society experiencing socio-
economic hardships. METHODS: In 234 verified mild to
moderate EH (mean age 47.8  12.2 years, 117 males,
117 females) the QL assessment was performed using the
well-validated, self-administered questionnaires: The Giessen
Somatic Complaints Questionnaire (GSC) and The Gen-
eral Well-Being Adjustment Scale (GWB). At the same
time, C with previously recommended antihypertensive
